New Hampshire Department of Justice

07/15/2025 | Press release | Archived content

Attorney General Formella Helps Secure Over $200 Million from Gilead Sciences for Illegal Kickbacks

Concord, NH - Attorney General John M. Formella today announced that he, along with a coalition of 48 of his fellow attorneys general, has secured $202 million from Gilead Sciences, Inc. (Gilead) for running an illegal kickback scheme to promote its HIV medications.

"This settlement holds Gilead accountable for abusing our health care system and defrauding taxpayers through illegal kickbacks," said Attorney General Formella. "No company is above the law, and this resolution sends a strong message that we will not tolerate corporate schemes that prioritize profits over ethics and patient care."

Gilead violated federal law by illegally providing incentives - including awards, meals, and travel expenses - to health care providers prescribing Gilead's medications, resulting in millions of dollars in false claims submitted to government health care programs.

From January 2011 to November 2017, Gilead violated federal anti-kickback laws by providing gifts to health care providers who attended and spoke at promotional speaker programs for Gilead's HIV drugs: Stribild, Genvoya, Complera, Odefsey, Descovy, and Biktarvy. Gilead paid high-volume prescribers tens to hundreds of thousands of dollars to present as "HIV Speakers." The company also paid travel expenses for speakers traveling to attractive destinations such as Hawaii, Miami, and New Orleans, and hosted dinners at high-end restaurants.

Gilead failed to adopt internal compliance mechanisms to prevent its sales representatives from improperly offering incentives to induce prescriptions.

The settlement, reached in coordination with the U.S. Department of Justice and approved by the U.S. District Court for the Southern District of New York, provides $49 million for Medicaid programs nationwide, including $21,541 for New Hampshire, with the remainder going to Medicare, Tricare, and the AIDS Drug Assistance Program (ADAP).

New Hampshire's settlement allocation reflects several positive health and demographic factors, such as the state's smaller population, low per capita HIV incidence rates, and relatively low Medicaid enrollment.

New Hampshire Department of Justice published this content on July 15, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 17, 2025 at 19:44 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io